Comments
Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil and Chlorthalidone tablets, 40 mg/12.5 mg and 40 mg/25 mg.
The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ - II, India.
Zydus Lifesciences stock rose 1.02 per cent on the NSE to trade at ₹1,101.65 as of 12.19 pm.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.